News
LJPC
--
0.00%
--
La Jolla Pharmaceutical announces CMO departure
La Jolla Pharmaceutical (LJPC) says Lakhmir Chawla, M.D., Chief Medical Officer gave notice of his intent to resign effective October 2.Dr. Chawla is expected to enter into a consulting agreement with
Seekingalpha · 4d ago
Independent Director David Ramsay Just Bought A Handful Of Shares In La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Potential La Jolla Pharmaceutical Company (NASDAQ:LJPC) shareholders may wish to note that the Independent Director...
Simply Wall St. · 08/25 13:31
La Jolla Pharmaceutical Director Ramsay Buys 47,000 @ Avg Price: $3.99
-Form 4
Benzinga · 08/24 20:29
La Jolla Pharmaceutical (NASDAQ:LJPC) Share Prices Have Dropped 87% In The Last Five Years
We're definitely into long term investing, but some companies are simply bad investments over any time frame. It hits...
Simply Wall St. · 08/21 19:02
La Jolla Pharmaceutical EPS misses by $0.13, misses on revenue
La Jolla Pharmaceutical (NASDAQ:LJPC): Q2 GAAP EPS of -$0.57 misses by $0.13. Revenue of $5.81M (+1.9% Y/Y) misses by $2.29M. Shares -3.97% PM. Press Relea
seekingalpha · 08/06 18:11
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2020 and Highlights Recent Corporate Progress
SAN DIEGO, California, Aug. 06, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening disea
GlobeNewswire · 08/06 12:30
Merger Arbitrage Mondays - Siemens Healthineers To Acquire Varian Medical Systems
Seeking Alpha - Article · 08/03 10:00
La Jolla Pharmaceutical high on president&CEO appointment
Seeking Alpha · 07/28 20:56
Larry Edwards Appointed President and Chief Executive Officer of La Jolla Pharmaceutical Company
SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that its Board of Directors has appointed Larry Edwards as President and Chief Executive Officer. “Larry has an impressive track record bringing innova
GlobeNewswire · 07/28 20:16
La Jolla Pharmaceutical Company Announces the Closing of Acquisition of Tetraphase Pharmaceuticals, Inc.
-Combined Company Offers Two Innovative Therapies to Treat Patients Suffering from Life-threatening Diseases-SAN DIEGO, California and WATERTOWN, Massachusetts, July 28, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicate
GlobeNewswire · 07/28 20:15
Merger Arbitrage Mondays - A Large Acquisition Ends The Energy Sector Deal Drought
Seeking Alpha · 07/27 10:47
Merger Arbitrage Mondays - Forescout And Advent Settle Their Differences
Seeking Alpha - Article · 07/20 13:18
Merger Arbitrage Mondays - Dime Community Bancshares And Bridge Bancorp Combine In Merger Of Equals
Seeking Alpha - Article · 07/06 14:11
Merger Arbitrage Mondays - Tetraphase Pharmaceuticals Finds A New Home
Seeking Alpha - Article · 06/29 11:16
The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24)
Benzinga · 06/25 12:26
La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.
GlobeNewswire · 06/24 12:30
La Jolla to acquire Tetraphase Pharma
Seeking Alpha - Article · 06/24 11:53
UPDATE: Total Value Of La Jolla Purchase Of Tetraphase $43M In Upfront Cash Plus Potential Future Cash Payments Of Up To $16M
Benzinga · 06/24 11:33
UPDATE: Tetraphase Shareholders Will Be Entitled To Receive 1 Non-Tradeable Contingent Value Right
Tetraphase equity holders would also be entitled to receive, for each share of Tetraphase common stock, one non-tradeable CVR. The holders of the CVRs would be entitled to receive payments of up to an additional $16.0
Benzinga · 06/24 11:32
La Jolla Pharma To Purchase Tetraphase Pharma For Upfront Payment Of $2/Share Of Tetraphase Common Stock, $2.68/Share Of Tetraphase Stock Underlying Nov. 2019 Warrants , $2.69/Share Tetraphase Stock Underlying Jan. 2020 Warrants
Benzinga · 06/24 11:31